Arrowstreet Capital
NTLA icon

Arrowstreet Capital’s Intellia Therapeutics NTLA Stock Holding History

Arrowstreet Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.5M Buy
3,280,760
+1,883,517
+135% +$26.4M 0.02% 519
2026
Q1 		$17.9M Buy
+1,397,243
New +$17.8M 0.01% 780
2020
Q1 		– Sell
-14,600
Closed -$214K – 2040
2019
Q4 		$214K Buy
+14,600
New +$203K ﹤0.01% 1613

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Arrowstreet Capital's NTLA Position: Q2 2026 in Review

Arrowstreet Capital increased its Intellia Therapeutics (NTLA) stake by 135% in Q2 2026, buying an estimated $26.4M and bringing the position to 3,280,760 shares worth $55.5M. The position accounts for 0.02% of the portfolio, ranked #519.

Arrowstreet Capital first reported a position in NTLA in Q4 2019 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Arrowstreet Capital held 3,280,760 shares of Intellia Therapeutics worth $55.5M as of Q2 2026.
  • Arrowstreet Capital bought 1,883,517 Intellia Therapeutics shares in Q2 2026, an estimated $26.4M.
  • Intellia Therapeutics made up 0.02% of Arrowstreet Capital's portfolio in Q2 2026, its #519 holding.
  • Arrowstreet Capital first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.